Bibliography

The team at Novosys Health has authored more than 300 scientific manuscripts and conference presentations and abstracts. Several of these publications were awarded clinical awards by clinical societies and foundations.


MANUSCRIPT PUBLICATIONS

1.      Kim MH, Bell KF, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Healthcare burden of dyspepsia among nonvalvular atrial fibrillation patients. J Manag Care Pharm. Accepted 2013.

2.      Miao R, Wei W, Lin J, Xie L, Baser O. Does device make any difference? A real-world retrospective study of insulin treatment among elderly patients with type-2 diabetes. J Diabetes Sci Tech. Accepted 2013.

3.      Amin  A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Comparison of medical costs of atrial fibrillation patients unsuitable for warfarin treated with apixaban or aspirin, based on AVERROES trial. Clin Appl Thromb Hemost. 2013

4.      Deitelzweig S, Amin  A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Medical costs of oral anticoagulants vs warfarin for atrial fibrillation patients with different stroke risks. Cardiol Therapy. 2013;

5.      Deitelzweig S, Amin  A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among nonvalvular atrial Fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials. J Med Econ. 2013;16:1163-8.

6.      Offord S, Lin J, Wong B, Mirski D, Baker RA. Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage. Comm Ment Health J. 2013;

7.      Bera R, Offord S, Zubek D, Lau G, Lin J, Karson C. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy. J Clin Pharmacol. 2013;

8.      Lin J, Preblick R, Lingohr-Smith M, Kwong WJ. Incremental healthcare resource utilization and economic burden of venous thromboembolism recurrence from a US payer perspective. J Manag Care Pharm. 2013;

9.      Reynolds MR, Lin J, Jhaveri M, Mozaffari E, Plich A. Estimation of Potential Cost Savings Associated With Reduced Rates of Cardiovascular Hospitalization Among Atrial Fibrillation/Flutter Patients Treated With Dronedarone in the ATHENA Trial. Am J Ther. 2013 Jan 23.

10.   Lin J, Chow W, Kim MS, Rupnow MF. Real-world treatment pattern and outcomes among patients who took tapentadol IR or oxycodone IR. J Med Econ. 2013;16:685-90.

11.   Lin J, Wong B, Offord S, Mirski D. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications vs. oral among patients with schizophrenia. J Behav Health Serv Res. 2013;40:355-66.

12.   Offord S, Lin J, Mirski D, Wong B. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther. 2013;

13.   Khorana AA, Dalal MR, Lin J, Connolly GC. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res. 2013;5:101-8.

14.   Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs. oral. J Med Econ.  2013;16(2):231-9.

15.   Amin A, Lin J, Thompson S, Wiederkehr D. Rate of deep-vein thrombosis and pulmonary embolism during the care continuum in patients with acute ischemic stroke in the United States. BMC Neurology. 2013;13:17.

16.   Deitelzweig SD, Amin A, Christian R, Friend K, Lin J, Lowe TJ. Health care utilization, costs, and readmission rates associated with hyponatremia. Hospital Practice. 2013;41:89-95.

17.   Amin A, Deitelzweig S, Christian R, Friend K, Lin J, Lowe TJ. Healthcare resource burden associated with hyponatremia among patients hospitalized for heart failure in US. J Med Econ. 2013;16(3)415-20.

18.   Deitelzweig S, Amin A, Christian R, Friend K, Lin J, Lowe TJ. Hyponatremia-associated healthcare burden among US patients hospitalized for cirrhosis. Adv Ther. 2013;30(1):71-80.

19.   Connolly GC, Dalal M, Lin J, Khorana AA. Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer. 2012;78(3):253-8.

20.   Amin A, Deitelzweig S, Christian R, Friend K, Lin J, Belk K, Baumer D, Lowe TJ. Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the US. J Hosp Med. 2012 Oct;7(8):634-9.

21.   Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013 Feb 1;119(3):648-55.

22.   Dasta JF, Chiong JR, Christian R, Friend K, Lingohr-Smith M, Lin J, Cassidy IB. Update on tolvaptan for the treatment of hyponatremia. Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):399-410.

23.   Pineo GF, Lin J, Annemans L. The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients. Clinicoecon Outcomes Res. 2012;4:99-107.

24.   Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 2012;15(4):776-85.

25.   Dasta JF, Chiong JR, Christian R, Lin J. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials. Hosp Pract (Minneap). 2012 Feb;40(1):7-14.

26.   Amin AN, Jhaveri M, Lin J. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors. Adv Ther. 2011 Oct;28(10):907-26.

27.   Lepercq J, Lin J, Hall GC, Wang E, Dain MP, Riddle MC, Home PD. Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy. Obstet Gynecol Int. 2012;2012:649070.

28.   Amin AN, Jhaveri M, Lin J. Temporal pattern and costs of rehospitalization in atrial fibrillation/atrial flutter patients with one or more additional risk factors. J Med Econ. 2012;15(3):548-55.

29.   Guérin A, Lin J, Jhaveri M, Wu EQ, Yu AP, Cloutier M, Gauthier G, Alpert JS. Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy. Int J Cardiol. 2012 Feb 13.

30.   Chiong JR, Kim S, Lin J, Christian R, Dasta JF. Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. J Med Econ. 2012;15(2):276-84.

31.   Amin A, Varker H, Princic N, Lin J, Thompson S, Johnston S. Duration of Venous Thromboembolism Risk Across a Continuum in Medically-Ill Hospitalized Patients. J Hosp Med. 2012 Mar;7(3):231-8.

32.   Kim MH, Smith PJ, Jhaveri M, Lin J, Klingman D. One Year Treatment Persistence and Potential Adverse Events Among Patients with Atrial Fibrillation Treated With Amiodarone or Sotalol: A Retrospective Claims Database Analysis. Clin Ther. 2011 Nov;33(11):1668-1681.

33.   Naccarelli GV, Johnson SS, Dalal M., Lin J, Patel PP. Rates and Implications for Hospitalization of Patients ≥65 Years of Age with Atrial Fibrillation/Flutter. Am J Cardiol. 2011 Nov 23.

34.   Amin AN, Jhaveri M and Lin J. Incremental Cost Burden to US Payers of Atrial Fibrillation/Atrial Flutter Patients with Additional Risk Factors. Adv Ther. 2011 Oct;28(10):907-26.

35.   Joish VN, Boklage S, Lynen R, Schmidt A, Lin J. Use of drospirenone/ethinyl estradiol (DRSP/EE) among women with acne reduces acne treatment–related resources. J Med Econ. 2011;14(6):681-9.

36.   Pineo G, Lin J, Stern L, Subrahmanian T, Annemans L. The Economic Impact of Enoxaparin Versus Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Patients with Acute Ischemic Stroke: A Hospital Perspective of the PREVAIL Trial. J Hosp Med. 2012 Mar;7(3):176-82.

37.   Amin AN, Lin J, Thompson S, Wiederkehr D. Real-World Rates of Inhospital and Post-Discharge Deep-Vein Thrombosis and Pulmonary Embolism in At-Risk Medical Patients in the US. Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):611-9.

38.   Amin AN, Lin J, Thompson S, Wiederkehr D. Inpatient and Outpatient Occurrence of Deep-Vein Thrombosis and Pulmonary Embolism and Thromboprophylaxis in US Patients Following Selected At-Risk Surgeries. Ann Pharmacother. 2011 Sep;45(9):1045-52.

39.   Deitelzweig SB, Lin J and Lin G. Preventing venous thromboembolism following orthopedic surgery in the United States: impact of special populations on clinical outcomes. Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):640-50.

40.   Merli GJ, Malangone E, Lin J, Lamerato L, Stern L. Real-world practices to prevent venous thromboembolism with pharmacological prophylaxis in US orthopedic surgery patients: An analysis of an integrated healthcare database.  J Thromb Thrombolysis. 2011 Jul;32(1):89-95.

41.   Amin A, Lenhart G, Princic N, Lin J, Thompson S, Johnston S. Retrospective Administrative Database Study of the Time Period of Venous Thromboembolism Risk During and Following Hospitalization for Major Orthopedic or Abdominal Surgery in Real-World US Patients. Hosp Pract (Minneap). 2011 Apr;39(2):7-17.

42.   Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol. 2011 Feb;86(2):217-20.

43.   Deitelzweig SB, Johnson BH, Lin J, and Schulman KL. Venous thromboembolism in the US: does race matter? J. Thromb Thrombolysis. 2011 Feb; 31(2):133-8.

44.   Pineo G, Lin J, Stern L, Subrahmanian T, Annemans L. Economic Impact of Enoxaparin after Acute Ischemic Stroke Based on PREVAIL. Clin Appl Thromb Hemost. 2011 Apr;17(2):150-7.

45.   Deitelzweig S, Lin J, Kreilick C, Hussein M, Battleman D. Warfarin Therapy in Patients with Venous Thromboembolism: Patterns of Use and Predictors of Clinical Outcomes. Adv Ther. 2010 Sep;27(9):623-33. Epub 2010 Jul 30.

46.   Kim MH, Lin J, Foltz Boklage SH, Kreilick CA. Total costs and atrial fibrillation ablation success or failure in Medicare-aged patients in the US. Adv Ther. 2010 Sep;27(9):600-12. Epub 2010 Aug 9.

47.   Deitelzweig S, Lin J, Hussein M, Battleman D. Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis? J Thromb Thrombolysis. 2010 Jul;30(1):55-66.

48.   Naccarelli GV, Johnson SS, Lin J, Patel PP, Schulman KL. Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA-Like Patients with Atrial Fibrillation/Atrial Flutter in the United States. Clin Cardiol. 2010 May;33(5):270-9

49.   Amin, AN, Lin J, Johnson BH and Schulman KL. Clinical and economic outcomes with appropriate or partial prophylaxis. Thromb Res. 2010 Jun;125(6):513-517.

50.   Amin AN, Lin J and Ryan A. Lack of Thromboprophylaxis Across the Care Continuum in US Medical Patients. Hosp Pract (Minneap). 2010 Jun;38(3):17-25.

51.   Zimetbaum, PJ, Thosani A, Yu H, Xiong Y, Lin J, Kothawala P, Emons M. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Amer J Med. 2010 May;123(5):446-53.

52.   Merli G, Ferrufino CP, Lin J, Hussein M, Battleman D. Hospital-based Costs Associated with Venous Thromboembolism Prophylaxis Regimens.  J Thromb Thrombolysis. 2010 May;29(4):449-58.

53.   Amin AN, Lin J, Ryan A. Need to Improve Thromboprophylaxis Across the Continuum of Care for Surgical Patients. Adv Ther. 2010 Feb;27(2):81-93.

54.   Kim MH, Lin J, Hussein M, Kreilick C and Battleman DS. Cost of atrial fibrillation in United States managed care organizations. Adv Ther. 2009 Sep;26(9):847-57

55.   Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing Prevalence Of Atrial Fibrillation And Flutter In The United States. Amer J Cardiol. 2009 Dec 1;104(11):1534-9.

56.   Kim MH, Klingman D, Lin J, Battleman DS.  Patterns and Predictors of Discontinuation of Rhythm-Control Therapy in Patients with Newly-Diagnosed Atrial Fibrillation.  Pharmacother. 2009 Dec;29(12):1417-26.

57.   Kim MH, Lin J, Hussein M and Battleman D. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy. Curr Med Res Opin. 2009 Dec;25(12):3037-47.

58.   Ishak J., Proskorovsky I., Guo S., Lin J., Caro J. Persistence with anti-arrhythmics and its impact on atrial fibrillation-related outcomes. Amer J Pharm Benefits. 2009;1(4):193-200.

59.   Kim MH, Lin J and Kreilick C. National Assessment of Medicare Prescription-Plan Coverage Gaps Among Atrial Fibrillation Patients in the United States. Adv Ther. 2009 Aug;26(8):784-94.

60.   Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. J Thromb Thrombolysis. 2009 Nov;28(4):458-64.

61.   Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of venous thromboembolism occurrence in medical patients among the insured population. Thromb Haemost. 2009 Nov;102(5):951-7.

62.   Amin AN, Lin J, Lenhart G, Schulman KL. Clinical and economic outcomes in patients at risk for venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. Thromb Haemost. 2009 Aug;102(2):321-6.

63.   Amin AN,  Stemkowski S, Lin J, Yang G. Thromboprophylaxis use in US Hospitals: Adherence to the Seventh American College of Chest Physician’s Recommendations for At-Risk Medical and Surgical Patients. J Hosp Med. 2009 Oct;4(8):E15-21

64.   Amin AN, Lin J, Yang G, Stemkowski S. Are there any differences in the clinical and economic outcomes between US cancer patients receiving appropriate or inappropriate VTE prophylaxis? J Oncol Pract. Vol 5, No 4 (July), 2009: 159-164.

65.   Kim MH, Lin J, Hussein M, Battleman, D. Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation. Curr Med Res Opin, May 2009, Vol. 25, No. 5, 1215-1220.

Accompanied by an Editorial Commentary: Burden of atrial fibrillation. Chee W. Khoo and, Gregory Y. H. Lip Current Medical Research and Opinion, May 2009, Vol. 25, No. 5, 1261-1263

66.   Kim M, Klingman D, Lin J, Pathak P, Battleman D. Cost of Hospital Admission for Antiarrhythmic Drug Initiation in Atrial Fibrillation in the United States, Ann Pharmacother. 2009 May; 43(5):840-8.

67.   Amin A, Stemkowski S, Lin J, Yang G. Appropriate thromboprophylaxis in hospitalized cancer patients. Clin Adv Hemat Oncol, Vol. 6, Issue 12, Dec 2008: 910-920.

68.   Baroletti S, Piovella C, Fanikos J, Labreche M, Lin J, Goldhaber SZ. Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes. Thromb Haemost. 2008, 100 6: 1130-1135.

69.   Deitelzweig S, Becker R, Lin J, Benner J.  Comparison of the 2-year clinical and economic outcomes of VTE prophylaxis options in medical patients at risk of VTE. Thromb Haemost. 2008 100 5: 810-820.

70.   Merli G, Ferrufino C, Lin J, Hussein M, Battleman, D. Hospital-based costs associated with VTE treatment regimens. J Thromb Haemost. 2008 Jul; 6(7):1077-86.

71.   Amin A, Stemkowski S, Lin J, Yang G. Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis? Thromb Haemost. Apr 2008; 99(4):796-7.  

72.   Spyropoulos AC, Lin J.  Direct Medical Costs of Venous Thromboembolism and Subsequent Hospital Readmission Rates: An Administrative Claims -- Analysis From 30 Managed Care Organizations. J Manag Care Pharm. Aug. 2007, Vol 13, Issue 6, 475-486.

73.   Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost, Aug. 2007 - Vol. 5 Issue 8, 1610–1616.

Accompanied by an editorial comment: Goldhaber SZ. Preventing pulmonary embolism and deep vein thrombosis: a 'call to action' for vascular medicine specialists. J Thromb Haemost. 2007 Aug;5(8):1607-9.

74.   Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Amer J Health Syst Pharm. 2007 Jan 1;64(1):69-76.

75.   MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Amer J Health Syst Pharm. 2006; Volume 63.

 

ABSTRACTS AND CONFERENCE PRESENTATIONS

1.      Karson C, Offord S, Baker R, Eramo A, Lin J, Kamat S. Inpatient resource utilization and cost-related benefits of long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. American College of Neuropsychopharmacology (ACNP) Annual Meeting 2013, Poster

2.       O'Neal D, Charbonnel B, Wang E, Lin J, Davies, MJ, Fonseca V. Meta-analysis of randomized controlled trials of lixisenatide as add-on to basal insulin ± OADs in patients with type 2 diabetes mellitus. The Annual Scientific Meeting of the Australian Diabetes Society and Australian Diabetes Educators Association, 2013, Poster.

3.      Onishi Y, Inagaki N, Ikeda Y, Admane K, Lin J, Van Gaal L, Seino Y. Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus: a meta-analysis of 2 randomized controlled trials. European Association for the Study of Diabetes (EASD) Annual Meeting, 2013, Poster A-13-2244 EASD

4.      Hanefeld M, Berria R, Lin J, Aronson R, Darmon P, Evans M, Van Gaal L. Efficacy and safety of lixisenatide in elderly type 2 diabetes mellitus patients: subanalysis from the GetGoal programme. European Association for the Study of Diabetes (EASD) Annual Meeting, 2013, Poster A-13-1074 EASD

5.      Meier JJ, Yabe D, Wang E, Lin J, Rosenstock J, Ahren B. Efficacy of lixisenatide in patients with different levels of beta-cell function as assessed by C-peptide/glucose ratio. European Association for the Study of Diabetes (EASD) Annual Meeting, 2013, Poster A-13-929-EASD

6.      Puig Domingo ML, Fonseca V, Wang E, Lin J, Davies M, Tinahones FJ, Charbonnel B. Meta-analysis of randomized controlled trials of lixisenatide as add-on to basal insulin and/or oral antidiabetic drugs in patients with type 2 diabetes mellitus. European Association for the Study of Diabetes (EASD) Annual Meeting, 2013, Poster A-13-1044-EASD

7.      Raccah D, Ceriello A, Gourdy P, Sagnard L, Lin J, Rosenstock J. Meta-analysis of GLP-1 agonist lixisenatide use in patients insufficiently controlled with OADs. European Association for the Study of Diabetes (EASD) Annual Meeting, 2013, Poster A-13-807-EASD

8.      Wong B, Offord S, Mirski D, Zubek D, Lin J, Baker RA. Adherence, outcomes and the schizophrenia patient: data for case managers. CMSA's 23rd Annual Conference, 2013, Poster.

9.      Karson C, Kamat S, Offord S, Zubek D, Lin J, Eramo A, Gutierrez B. Impact of switching from oral to long-acting injectable antipsychotic medications among Medicaid-insured patients with schizophrenia. NCDEU 53rd Annual Meeting, 2013, Poster.

10.   Fonseca V, Wang E, Lin J, Guerci B, Evans M, Vidal J, Freemantle N. Basal insulin + lixisenatide induces less symptomatic hypoglycemia and weight gain than basal bolus. American Diabetes Association (ADA), 2013, Poster.

11.   Rosenstock J, Germe M, Wang E, Lin J, Bonadonna RC, de Pablos-Velasco P, Roussel R, Raccah D. Expanding the basal-plus regimen: basal insulin + lixisenatide is more likely to achieve the composite outcome of HbA1c<7%, no documented symptomatic hypoglycemia and no weight gain compared with basal + prandial insulin. American Diabetes Association (ADA), 2013, Poster.

12.   Charbonnel B, Wang E, Lin J, Davies M, Fonseca V. Meta-analysis of randomized controlled trials of lixisenatide as add-on to basal insulin in patients with type 2 diabetes mellitus. American Diabetes Association (ADA), 2013, Poster.

13.   Raccah D, Ceriello An Gourdy P, Sagnard L, Lin J, Rosenstock J. Meta-analysis of GLP-1 agonist lixisenatide use in patients insufficiently controlled with oral antidiabetic drugs suggest improved results in efficacy, hypoglycemia and weight gain. American Diabetes Association (ADA), 2013, Poster.

14.   Hanefeld M, Berria R, Lin J, Aronson R, Darmon P, Evans M, van Gaal L. Efficacy and safety of lixisenatide in elderly T2DM patients: subanalysis from the GetGoal program. American Diabetes Association (ADA), 2013, Poster.

15.   Seino Y, Inagaki N, Onishi Y, Ikeda Y, Admane K, Lin J, van Gaal L. Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus: a meta-analysis of 2 randomized controlled trials. American Diabetes Association (ADA), 2013, Poster.

16.   Zubek D, Wong B, Mirski D, Lin J, Offord S. Healthcare utilization findings important for nurses caring for patients with schizophrenia: poor early drug adherence negatively affects long-term patient outcomes. International Society of Psychiatric-Mental Health Nurses (ISPN), 2013, Poster.

17.   Zubek D, Wong B, Offord S, Baker RA, Mirski D, Lin J. Healthcare outcomes of patients with schizophrenia initiating long-acting injectable vs. oral antipsychotics: important implications for mental health nurses. International Society of Psychiatric-Mental Health Nurses (ISPN), 2013, Poster.

18.   Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Evaluation of medical costs associated with use of novel oral anticoagulants compared with warfarin among nonvalvular atrial fibrillation patients with moderate and high stroke risk. American Heart Association Quality of Care and Outcomes Research (AHA QCOR), 2013, Oral Presentation.

19.   Kim M, Bell KF, Makenbaeva D, Wiederkehr D, Lin G, Graham J. Healthcare burden associated with dyspepsia among nonvalvular atrial fibrillation patients. American Heart Association Quality of Care and Outcomes Research (AHA QCOR), 2013, Poster.   

20.   Kim M, Makenbaeva D, Bell KF, Wiederkehr D, Lin G, Graham J. Impact of gastrointestinal disorders among nonvalvular atrial fibrillation patients on healthcare resource usage and costs. American Heart Association Quality of Care and Outcomes Research (AHA QCOR). 2013, Poster.

21.   Kamat S, Gutierrez B, Eramo A, Zubek D, Baker RA, Lin J, Karson C. Early assessment of real-world usage of second generation long-acting injectable paliperidone palmitate among commercially and Medicaid insured schizophrenia patients International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2013, Poster.

22.   Karson C, Offord S, Zubek D, Kamat S, Docherty J, Lin J, Gutierrez B. Reduction of Hospitalizations and Costs among Medicaid Insured Schizophrenia Patients After Initiating Long-Acting Injectable Antipsychotics. American Psychiatric Association (APA), 2013, Poster.

23.   Kamat S, Zubek D, Offord S, Karson C, Docherty J, Lin J, Gutierrez B. Commercially Insured Schizophrenia Patients Use Fewer Inpatient Resources and Incur Lower Costs After Initiating Long-Acting Injectable Antipsychotics. American Psychiatric Association (APA), 2013, Poster.

24.   Schwartz DA, Eichner SF, Lin J, Skup M, Yang M, Mulani PM, Chao J. Comparison of Health Care Utilization and Costs Among Patients With Fistulizing Crohn’s Disease Treated With Biologics With or Without Prior Seton Procedure. European Crohn's and Colitis Organisation (ECCO), 2013, Poster.

25.   Bera R, Offord S, Zubek D, Lau G, Lin J, Baker RA, Karson C. Comparison of Healthcare Resource Usage and Costs Before and After Initiating Treatment with Long-Acting Injectable Antipsychotics among Medicaid Insured Schizophrenia Patients. Academy of Managed Care Pharmacy (AMCP), 2013, Poster.

26.   Wong B, Offord S, Mirski D, Zubek D, Lin J, Baker RA. Adherence, Outcomes and the Schizophrenia Patient: Data for Case Managers. Case Management Society of America (CMSA), 2013, Poster.

27.   Kim MH, Bell KF, Makenbaeva D, Wiederkehr D, Lin J and Graham J. Incremental Healthcare Burden Associated with Dyspepsia Among Nonvalvular Atrial Fibrillation Patients:  Implications for Anticoagulation Therapy.  International Stroke Conference (ISC), 2013, Poster.

28.   Karson C, Bera R, Offord S, Zubek D, Lau G and Lin J. Comparison of Healthcare Resource Usage and Costs Before and After Initiating  Long-Acting Injectable Antipsychotics among Medicaid Insured Patients with Schizophrenia. International Congress On Schizophrenia Research (ICOSR), 2013.

29.   Bera R, Karson C, Offord S, Zubek D, Lau G and Lin J. Persistent Usage of Long-Acting Injectable Antipsychotics is Associated with Reductions in Hospitalization Rates and Costs for Medicaid Insured Patients with Schizophrenia. International Congress On Schizophrenia Research (ICOSR), 2013.

30.   Karson C, Bera R, Offord S, Zubek D, Lau G and Lin J. Evaluation of Economic Healthcare Impact of Initiating Long-Acting Injectable Antipsychotic Therapy among Medicaid Insured Patients with Schizophrenia. American College of Neuropsychopharmacology (ACNP), 2012, Poster.

31.   Bera R, Karson C, Offord S, Zubek D, Lau G and Lin J. Impact on Hospitalization After Initiating Long-Acting Formulation Antipsychotics for a Longer vs. Shorter Time Period among Medicaid Insured Patients with Schizophrenia. American College of Neuropsychopharmacology (ACNP), 2012, Poster.

32.   Bera R, Offord S, Zubek D, Lau G, Lin J and Karson C. Impact on Healthcare Resource Usage and Costs among Medicaid Insured Schizophrenia Patients who Initiated Long-Acting Injectable Antipsychotics. U.S. Psychiatric and Mental Health Congress, 2012, Poster.

33.   Bera R, Offord S, Zubek D, Lau G, Lin J and Karson C. Evaluation of Hospitalization Resource Usage among Medicaid Insured Patients with Schizophrenia with Different Treatment Duration of Long-Acting Injectable Antipsychotic Therapy. U.S. Psychiatric and Mental Health Congress, 2012, Poster.

34.   Wong B, Offord S, Lin J and Mirski D. Early-on Discontinuation of Antipsychotic Therapy among Schizophrenia Patients is Predictive of Nonadherence Later on in the Course of the Illness. U.S. Psychiatric and Mental Health Congress, 2012, Poster.

35.   Offord S, Mirski D, Lin J and Wong B. Healthcare Impact of Schizophrenia Patients Initiating Long-Acting Injectable vs. Oral Antipsychotics. U.S. Psychiatric and Mental Health Congress, 2012, Poster.

36.   Schwartz DA, Eichner SF, Lin J, Skup M, Yang M, Mulani PM,  Chao J.  Comparison of health care utilization and costs among patients with fistulizing Crohn’s disease treated with biologics with or without prior seton procedure. American College of Gastroenterology (ACG), 2012, Poster.

37.   Cross R, Flasar M, Patil S, Lin J, Yang M, Mulani PM, Chao J. Use of Anti-TNF Agents in Crohn’s Disease Is Associated With Larger Reductions in Diagnostic Imaging and Radiation Doses Compared With Systemic Steroids in the Year Following Initiation of Therapy. American College of Gastroenterology (ACG), 2012, Poster.

38.   Lin J, Chow W, Mody S and Rupnow M. Real-world Evaluation of Adverse Event Related Outcomes in Hospitalized Patients using Tapentadol IR vs. Oxycodone IR. American Society of Regional Anesthesia and Pain Medicine (ASRA) 2012 conference, Poster.

39.   Lin J, Chow W, Kim M and Rupnow M. Early Evaluation of Patient Characteristics, Hospital Length of Stay and Costs among Users of Tapentadol IR and Oxycodone IR. American Society of Regional Anesthesia and Pain Medicine (ASRA) 2012 conference, Poster.

40.   Chase P, Wang E, Cali A, Dain M-P, Lin J, Garg S. Glycemic Control and Safety of Insulin Glargine Among Type 1 Diabetes Patients in the United States: An Analysis of the IMPACT Database. American Diabetes Association Middle East (ADA-ME) Annual conference, 2012, Oral Presentation.

41.   Cali A., Dailey G., Lin J., Wang E. Evaluation of a Basal-Bolus Regimen in Patients With Type 2 Diabetes Mellitus of Different Ages: A Pooled Analysis. World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy) 2012 conference, Poster.

42.   Dain M-P, Cali A., Del Prato S., Lankisch M., Lin J., Owens D.R., Dailey G. Evaluation of a Basal-Plus Regimen in Patients With Type 2 Diabetes Mellitus of Different Ages: A Pooled Analysis. World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy) 2012 conference, Poster.

43.   Chase P, Wang E, Cali A, Dain M-P, Lin J, Garg S. Efficacy and Safety of Insulin Glargine among Type 1 Diabetes Patients in the US: Analysis of the IMPACT Database. World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy) 2012 conference, Oral Presentation.

44.   Kadowaki T, Odawara M, Lin J, Ohtani T, Ito T, Admane K. Glycemic Control and Hypoglycemia Prevalence in Japanese Subjects With Type 2 Diabetes According to Age: An ALOHA Study Subanalysis. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

45.   Pan C, Admane K, Zhang Q, Wang E, Lin J, Ning G. Analysis of Pooled Clinical Trial Data for Insulin Glargine vs NPH in Asian Insulin-Naïve Patients With Type 2 Diabetes. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

46.   Wang J, Ji L, Shang S, Wang E, Lin J, Admane K. Glycemic Control and Hypoglycemia Prevalence in Chinese T2DM Patients Treated with Insulin Glargine or NPH: An Analysis of the FINE Asia Registry Population. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

47.   Chiorean, M, Yang M, Lomax K, Rizzo J, Mulani P, Chao J. Reduction in Colectomy and Related Healthcare Costs in Ulcerative Colitis Patients Treated with Adalimumab Compared With Immunosuppressants or Steroids. Digestive Disease Week 2012, Poster.

48.   Ji L, Wang E, Lin J, Shang S, Admane K. Initiation of Basal Insulin in Chinese Patients With Type 2 Diabetes: An Analysis of the FINE Asia Registry. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

49.   Yang J, Wang J, Admane K, Wang E, Lin J, Ji L. Predictors of Hypoglycemia in the Real-World Management of Asian Patients With T2DM: A FINE-Asia Registry Analysis. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

50.   Yang Y, Wang E, Lin J, Shang S, Admane K, Ji L. Impact of Gender on Glycemic Control and Safety in the Management of Asian Patients With Type 2 Diabetes: A Subanalysis of the FINE-Asia Registry. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

51.   Ning G, Wang E, Zhang Q, Lin J, Admane K. Analysis of Pooled Clinical Trial Data for Insulin Glargine vs NPH in Asian Insulin-Naïve Patients With Type 2 Diabetes Stratified by BMI. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

52.   Fanelli CG, Porcellati F, Lin J, Wang E, Lucidi P, Bolli GB. Glycemic Control and Hypoglycemia Prevalence According to BMI: An Analysis of RCT Data. American Diabetes Association Middle East (ADA-ME) Annual conference, 2012, Oral Presentation.

53.   Odawara M, Admane K, Lin J, Wang E, Ohtani T, Kadowaki T. Glycemic Control and Hypoglycemia Prevalence by BMI in Japanese Patients With Type 2 Diabetes: ALOHA Study Sub-Analysis. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

54.   Ohtani T, Kadowaki T, Admane K, Lin J, Wang E, Odawara M. Glycemic Control and Hypoglycemia Prevalence by Age in Japanese Subjects With Type 2 Diabetes: ALOHA Study Subanalysis. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

55.   Pan C, Admane K, Zhang Q, Lin J, Wang E, Ning G. Pooled Clinical Trial Analysis of Insulin Glargine vs NPH in Insulin-Naïve Asian Patients With Type 2 Diabetes Mellitus. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

56.   Wang J, Admane K, Wang E, Lin J, Ji L. Glycemic Control and Hypoglycemia Prevalence in Chinese T2DM Patients Treated with Insulin Glargine or NPH: FINE Asia. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

57.   Ji L, Admane K, Lin J, Wang E, Wang J. Initiation of Basal Insulin in Chinese Patients With T2DM Inadequately Controlled by OADs: FINE Asia Registry Analysis. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

58.   Wang J, Admane K, Wang E, Lin J, Ji L. Predictors of Hypoglycemia in the Real-World Management of Asian Patients With T2DM: A FINE-Asia Registry Analysis. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

59.   Ji L, Admane K, Lin J, Wang E, Wang J. Impact of Gender on Glycemic Control and Safety in Managing Asian Patients With T2DM: A FINE-Asia Registry Subanalysis. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

60.   Cali A, Dailey G, Lin J, Wang E. A pooled analysis of patients with type 2 diabetes mellitus to evaluate the efficacy and safety of a basal-bolus regimen across different age groups. European Association for the Study of Diabetes (EASD) 2012, Poster.

61.   Bolli GB, Porcellati F, Lin J, Cali A, Wang E, Dain MP, Lucidi P, Fanelli CG. Reduction in HbA1c and Hypoglycaemia Rates With Insulin Glargine vs NPH in Treatment-Naïve Patients with Type 2 Diabetes Stratified by BMI: Pooled Analysis of 6 Clinical Trials. European Association for the Study of Diabetes (EASD) 2012, Poster.

62.   Wong B, Mirski D, Offord S and Lin J. Among patients with schizophrenia non-adherence to antipsychotic medications early-on results in more hospitalizations and greater healthcare costs. International Early Psychosis Association (IEPA), 2012, Poster.

63.   Offord S, Lin J, Mirski D and Wong B. Schizophrenic patients who discontinue antipsychotic medications early-on have a greater likelihood of non-adherence later on in the course of the illness. International Early Psychosis Association (IEPA), 2012, Poster.

64.   Lin J, Chow W, Mody S and Rupnow M. Real-world Evaluation of Adverse Event Related Outcomes in Hospitalized Patients using Tapentadol IR vs. Oxycodone IR. PainWeek 2012, Poster.

65.   Lin J, Chow W, Kim M and Rupnow M. Early Evaluation of Patient Characteristics, Hospital Length of Stay and Costs among Users of Tapentadol IR and Oxycodone IR. PainWeek 2012, Poster.

66.   Wong B, Offord S, Mirski D and Lin J. Characteristics associated with antipsychotic drug adherence among schizophrenic patients in a US managed care environment. Institute on Psychiatric Services (IPS) 2012, Poster.

67.   Baker R, Wong B, Offord S, Mirski D and Lin J. Antipsychotic drug adherence correlates with hospitalization rates and length of stay among Medicare and non-Medicare schizophrenia populations. Institute on Psychiatric Services (IPS) 2012, Poster.

68.   Mirski D and Lin J, Offord S and Wong B. The severity and demographics of schizophrenia patients switching to Depot antipsychotic agents. Institute on Psychiatric Services (IPS) 2012, Poster.

69.   Lin J, Wong B, Offord S and Mirski D. Managed care cost savings associated with the use of long-acting injectable formulations of antipsychotic agents in schizophrenia. Institute on Psychiatric Services (IPS) 2012, Poster.

70.   Offord S, Mirski D, Lin J and Wong B. Drug compliance and associated outcomes in schizophrenia patients before and after the initiation of depot antipsychotic agents. Institute on Psychiatric Services (IPS) 2012, Poster.

71.   Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J and Graham J. Predicting Impact Of Warfarin’s Time-In-Therapeutic Range On Stroke And Major Bleed Rates And Its Influence On Medical Cost Avoidance Associated With NOAC Usage– Learning From RE-LY, ROCKET-AF And ARISTOTLE Trials. Thrombosis and Hemostasis Summit of North America (THSNA) 2012, Poster.

72.   Odawara M, Wang E, Lin J, Admane K, Ito T and Kadowaki T. Glycemic Control and Hypoglycemia Prevalence in Japanese Participants With Type 2 Diabetes According to BMI: A Sub-Analysis of the ALOHA Data. American Diabetes Association (ADA) Annual conference, 2012, Poster.

73.   Raccah D,  Lin J, Bahloul A, Wang E and Penfornis A. Meta-analysis of Efficacy and Safety Outcomes Associated with the Basal-Plus Regimen of Insulin Glargine and Insulin Glulisine among Type 2 Diabetes Patients with HbA1c ≥8%. American Diabetes Association (ADA) Annual conference, 2012, Publication only.

74.   Kautzky-Willer A, Kosi L, Mihaljevic R, Lin J and Wang E. Glycemic Control and Hypoglycemia Prevalence According to Gender: An Analysis of RCT Data. American Diabetes Association (ADA) Annual conference, 2012, Poster.

75.   Garg S, Lin J, Wang E and Chase P. Evaluating Overall Glycemic Management of People With Type I Diabetes in the US. American Diabetes Association (ADA) Annual conference, 2012, Publication only.

76.   Lin J, Wei W, Vlajnic A, Pan C, Xie L, Baser O and Levin P. Real-world Practice Pattern and Outcomes of Patients with Type 2 Diabetes (T2DM) Initiating Injectable Therapy via Insulin Glargine Disposable Pen (GLA-P) or Liraglutide (LIRA). American Diabetes Association (ADA) Annual conference, 2012, Poster.

77.   Levin P, Wei W, Vlajnic A, Pan C, Xie L, Lin J and Baser O. Real-world Outcomes of Initiating Injectable Therapy with Insulin Glargine or Liraglutide among Patients With Type 2 Diabetes. American Diabetes Association (ADA) Annual conference, 2012, Oral Presentation.

78.   Owens DR, Del Prato S, Lin J, Wang E and Lankisch M. Impact of Diabetes Duration on Efficacy and Safety of a Basal-plus Regimen of Insulin Glargine Plus Once Daily Insulin Glulisine: a Pooled Analysis From 4 Clinical Trials. American Diabetes Association (ADA) Annual conference, 2012, Publication only.

79.   Dailey G, Lin J and Wang E. Efficacy and Safety of a Basal-Bolus Regimen of Basal Insulin Plus Insulin Glulisine in Patients With Type 2 Diabetes: A Pooled Analysis of 5 Clinical Trials. American Diabetes Association (ADA) Annual conference, 2012, Poster.

80.   Del Prato S, Lankisch M, Lin J, Wang E and Owens DR. Efficacy and Safety of a Basal-Plus Regimen of Insulin Glargine Plus Insulin Glulisine in Patients With Type 2 Diabetes: A Pooled Analysis of 4 Clinical Trials. American Diabetes Association (ADA) Annual conference, 2012, Poster.

81.   Lankisch MR, Owens DR, Wang E, Lin J and Del Prato S. Basal-Plus Regimen of Insulins Glargine and Glulisine Is Weight Neutral Across BMI Groups. American Diabetes Association (ADA) Annual conference, 2012, Publication only.

82.   Fanelli CG, Porcellati F, Lin J, Wang E, Lucidi P and Bolli GB. Glycemic Control and Hypoglycemia Prevalence According to BMI: An Analysis of RCT Data. American Diabetes Association (ADA) Annual conference, 2012, Publication only.

83.   Little S, Wang E, Lin J, Home P and Shaw J. Factors Influencing Prevalence of Hypoglycemia in RCTs of Previously Insulin-Naive People With Type 2 Diabetes. American Diabetes Association (ADA) Annual conference, 2012, Publication only.

84.   Lucidi P, Porcellati F, Lin J, Wang E, Bolli GB and Fanelli CG. Efficacy and Safety of Insulin Glargine vs NPH Insulin in Subjects With Type 2 Diabetes Mellitus Uncontrolled on Oral Agents: A Pooled Analysis of RCT Data. American Diabetes Association (ADA) Annual conference, 2012, Poster.

85.   Chase P, Lin J, Wang E and Garg S. Treatment of People With Type I Diabetes in the US: The Impact Database. American Diabetes Association (ADA) Annual conference, 2012, Poster.

86.   Mirski D, Offord S, Wong B, Lin J and Ross BA. Impact Of Antipsychotic Drug Adherence On The Management Of Schizophrenia Among US Medicare Patients. NEDEU 2012 Conference, by American Society of Clinical Psychopharmacology, Poster.

87.   Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J and Graham J. Medical Cost Avoidance among the General and Elderly Atrial Fibrillation Populations Differs According to Specific Anticoagulant Use, Based on the ARISTOTLE and RE-LY Trials. AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2012, Poster.

88.   Offord S, Mirski D, Lin J and Wong B. Drug compliance and associated outcomes in schizophrenia patients before and after the initiation of depot antipsychotic agents. American Psychological Association (APA) 2012, Oral Presentation.

89.   Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J and Graham J. Evaluation of Total Medical Costs with the Use of Apixaban and Rivaroxaban vs. Warfarin Among Atrial Fibrillation Patients. AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2012, Poster.

90.   Dasta JF, Chiong JR, Christian R and Lin J. Evaluation of Cost Offset Associated with Tolvaptan Usage Among Hyponatremic SIADH Patients in the US, Based on the SALT-1 and SALT-2 Trials. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Annual Conference, 2012, Poster.

91.   Pan C, Tangirala K, Wei W and Lin J. Health outcomes of initiating basal analog insulin via disposable pens among patients with type-2 diabetes in a US national managed care plan. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Annual Conference, 2012, Poster.

92.   Deitelzweig S, Amin A, Lin J, Christian R, Baumer B, Lowe TJ. Impact of Hyponatremia on Healthcare Resource Utilization in Decompensated Cirrhosis Patients. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Annual Conference, 2012, Poster.

93.   Wong B, Offord S, Mirski D and Lin J. Characteristics associated with antipsychotic drug adherence among schizophrenic patients in a US managed care environment. American Psychological Association (APA) 2012, Poster.

94.   Baker R, Wong B, Offord S, Mirski D and Lin J. Antipsychotic drug adherence correlates with hospitalization rates and length of stay among Medicare and non-Medicare schizophrenia populations. American Psychological Association (APA) 2012, Poster.

95.   Mirski D and Lin J, Offord S and Wong B. The severity and demographics of schizophrenia patients switching to Depot antipsychotic agents. American Psychological Association (APA) 2012, Poster.

96.   Lin J, Wong B, Offord S and Mirski D. Managed care cost savings associated with the use of long-acting injectable formulations of antipsychotic agents in schizophrenia. American Psychological Association (APA) 2012, Poster.

97.   Offord S, Mirski D, Lin J and Wong B. Drug compliance and associated outcomes in schizophrenia patients before and after the initiation of depot antipsychotic agents. American Psychological Association (APA) 2012, Poster.

98.   Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J and Graham J. Total Medical Costs Avoided with Apixaban versus Aspirin Treatment Among Atrial Fibrillation Patients Unable or Unwilling to Take Warfarin, Based on the AVERROES Trial Results. 2012 American College of Cardiology (ACC), Oral Presentation.

99.   Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J and Graham J. Comparison of Total Medical Cost Avoidance with the Usage of New Oral Anticoagulants Instead of Warfarin Among Atrial Fibrillation Patients, Based on the ARISTOTLE, RE-LY and ROCKET-AF Trials. 2012 American College of Cardiology (ACC), Poster.

100.          Lin J, Xie L, Wei W, Zhou S, Miao R, Pan C, Baser O. An Empirical Approach to Measure and Predict Treatment Persistence Among Insulin-glargine-treated Patients with Type 2 Diabetes. American Managed Care Pharmacy (AMCP) Annual Conference, 2012, Poster.

101.          Lin J, Miao R and Wei W. Real-world outcomes of switching from vial/syringe to disposable pen among elderly patients with type 2 diabetes mellitus who were treated with insulin glargine. American Managed Care Pharmacy (AMCP) Annual Conference, 2012, Poster.

102.          Lin J, Dalal M, Connolly G and Khorana AA. Evaluation of venous thromboembolism (VTE) risk among ambulatory patients with pancreatic cancer in a real-world setting.  ASCO, 2012 Gastrointestinal Cancers Symposium, Poster.

103.          Wong B, Offord S, Mirski D and Lin J. Epidemiology of schizophrenia patients initiating long-acting injectable vs. oral antipsychotics among the US Medicare and non-Medicare patient populations. American Psychological Association (APA) 2012, Oral Presentation.

104.          Dasta JF, Chiong JR, Christian R, Lin J. Estimation of Cost Savings Associated with Tolvaptan-mediated Length of Stay (LOS) Reduction among SIADH Patients in the US, Based on SALT-1 and SALT-2 Trials. Society of Critical Care Medicine (SCCM), Annual Conference, 2012, Poster.

105.          Lin J, Ling J, Wei W, Pan C. Outcomes of Initiating Insulin Glargine Therapy with Disposable Pen or Vial Among Patients with Type 2 Diabetes in a US Managed Care Health Plan. Diabetes Technology Meeting, 2011, Poster.

106.          Lin J, Miao R, Wei W. Does device make a difference? A real-world study of switching from vial to disposable pen among an employee population with type 2 diabetes mellitus who were treated with insulin glargine. Diabetes Technology Meeting, 2011, Poster.

107.          Dasta JF, Chiong JR, Kim S, Lin J. Evaluation Of The Hospital Resource Utilization Associated With Tolvaptan Usage Among Heart Failure Patients With Hyponatremia From The Everest Trial. American College of Clinical Pharmacy (ACCP) Annual Conference, 2011, Poster.

108.          Chiong JR, Dasta JF, Kim S, Lin J. Evaluation of Cost Savings Associated with Tolvaptan-mediated Length of Stay Reduction among Heart Failure Patients with Hyponatremia in the US, Based on the EVEREST Trial. American College of Chest Physicians (ACCP)-CHEST 2011. Oral Presentation.

109.          Amin A, Deitelzweig S, Lin J, Belk K, Christian R, Baumer D. and Lowe T. Consequences of Hyponatremia on Cost and Length of Stay in Heart Failure Patients. Annual Scientific meeting of the Heart Failure Society of America (HFSA), 2011, Poster.

110.          Deitelzweig S, Amin A, Lin J, Belk K, Christian R, Baumer D. and Lowe T. Impact of Hyponatremia on Mortality and Readmission Rates in Hospitalized Patients with Heart Failure. Annual Scientific meeting of the Heart Failure Society of America (HFSA), 2011, Poster.

111.          Little S, Wang E, Lin J, Home P, Shaw J. Factors influencing prevalence of hypoglycaemia in RCTs of previously insulin-naive people with type 2 diabetes. International Diabetes Federation (IDF) Conference 2011, Poster.

112.          Lankisch MR, Owens DR, Wang E, Lin J, Del Prato S. Dose Change in a Basal-Plus Regimen of Insulins Glargine and Glulisine Across BMI Groups. International Diabetes Federation (IDF) Conference 2011, Poster.

113.          Lee B, Williams C, Nichols GA, Herson M, Jones E and Lin J. Real-World Data Collection and Measurement of a QI-CME Activity to Improve Diabetes Care in a MCO. ALLIANCE FOR CME Annual Conference 2012, Poster.

114.          Amin A, Deitelzweig S, Lin J, Christian R, Baumer D. and Lowe T. Effect of SIADH on patient outcomes and healthcare resource utilization in hospitalized patients. International Society of Pharmacoeconomics and Outcomes Research - ISPOR Annual European Congress, 2011, Poster.

115.          Ji L, Wang E, Lin J and Tsai S.Variation of Glycemic Control and Patient Comorbidities With Duration of Type 2 Diabetes in Asian Patients: Analysis of the FINE Asia Registry. International Diabetes Federation (IDF) Conference 2011, Poster.

116.          Little S, Wang E, Lin J, Home P, Shaw J. Glycaemic Control and Hypoglycaemia Prevalence With Insulin Glargine versus NPH Insulin According to BMI: An Analysis of Pooled RCT Data. International Diabetes Federation (IDF) Conference 2011, Poster.

117.          Tsai S, Wang E, Lin J and Ji L. Differences in Dose, HbA1c, and Hypoglycaemia Between Insulin Therapies According to BMI:  A FINE Asia Subanalysis. International Diabetes Federation (IDF) Conference 2011, Poster.

118.          Reynolds MR, Zimetbaum PJ, Lin J, Jhaveri M, Mozaffari E and Plich A. Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial. Annual Meeting of the Society for Medical Decision Making 2011, Oral Presentation.

119.          Wang E, Lin J, Dain M and Dailey G. Differences in Glycaemic Reductions Between Insulin Therapies According to Body Mass Index: Pooled Results from Multinational Clinical Trials.  European Association for the Study of Diabetes (EASD) 2011, Poster.

120.          Lin J, Lepercq J, Hall G, Dain M, Riddle M, Home P. A Meta-Analysis of Maternal Outcomes in Pregnant Women Using Insulin Glargine Compared With NPH Insulin. European Association for the Study of Diabetes (EASD) 2011, Poster.

121.          Suastika K, Tsai S, Wang J, Kiat K, Wang E, Lin J, Ji L. Baseline Characteristics of the First Basal Insulin Evaluation in Asia (FINE Asia) Study Population. European Association for the Study of Diabetes (EASD) 2011, Poster.

122.  Wang J, Ji L, Suastika K, Kiat K, Wang E, Lin J, Tsai S. Initiation of Basal Insulin in Patients With Type 2 Diabetes: National Differences in Glycemic Control After 6 Months in a Subanalysis of the FINE Asia Database. European Association for the Study of Diabetes (EASD) 2011, Poster.

123.  Ji L, Suastika K, Wang J, Kiat K, Wang E, Lin J, Tsai S. Factors Associated with HbA1c Reduction in Asian Patients With T2DM: An Analysis of the FINE Asia Registry. European Association for the Study of Diabetes (EASD) 2011, Poster.

124.  Lin J, Khorana AA, Dalal M, Connolly G. Clinical and Economic Burden of Venous Thromboembolism Among U.S. Ambulatory Cancer Patients Undergoing Chemotherapy. Annual Congress of The International Society on Thrombosis and Haemostasis (ISTH), 2011, Poster.

125.  Khorana AA, Dalal M, Lin J, Connolly G. Venous Thromboembolism (VTE) in the Cancer Outpatient Setting: Contemporary Rates and Predictors in the U.S.  Annual Congress of The International Society on Thrombosis and Haemostasis (ISTH), 2011, Poster.

126.  Khorana AA, Connolly G, Dalal M, Lin J. Does bevacizumab increase the risk of venous thromboembolism? A cohort study. American Society of Clinical Oncologists (ASCO), 2011, Poster.

127.  Connolly G, Dalal M, Lin J, Khorana AA. Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. American Society of Clinical Oncologists (ASCO), 2011, Poster.

128.  Reynolds M, Zimetbaum PJ, Diamand F, Jhaveri M, Lin J, Plich A. US Cost Savings Resulting From The Dronedarone-Associated Reduction In Cardiovascular Hospitalizations Among Atrial Fibrillation/Flutter Patients In The ATHENA Trial: Full Study Analysis. AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2011, Poster.

129.  Alpert JS, Guerin A, Lin J, Jhaveri M and Wu EQ. Treatment Persistence Among Atrial Fibrillation/Flutter Patients on Combination Warfarin and Antiarrhythmic Drug Therapy in the Real-World Setting. AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2011, Poster.

130.  Joish V, Boklage S, Lin J, Lynen R. Use of drospirenone/ethinyl estradiol in women may reduce acne-related healthcare costs.  National Association of Nurse Practitioners in Women’s Health 14th Annual Premier Women’s Health Care Conference, 2011, Poster.

131.  Lepercq J, Lin J, Hall G, Dain M, Riddle M, Home P. Maternal and Neonatal Outcomes in Pregnant Women Treated With Insulin Glargine versus NPH Insulin: A Meta-Analysis of Published Studies.  American Diabetes Association (ADA) Annual conference, 2011, Poster.

132.  Amin A, Varker H, Lin J, Thompson S and Johnston S. Duration of Risk of VTE in US Medical Patients. Society of General Internal Medicine (SGIM) Annual Conference, 2011, Poster.

133.  Amin A, Jhaveri M and Lin J. Rehospitalization Rates and Costs in Hospitalized ATHENA-Like Patients With Atrial Fibrillation/Atrial Flutter. Society of General Internal Medicine (SGIM) Annual Conference, 2011, Poster.

134.  Deitelzweig S, Amin A, Lin J, Belk K, Baumer D. and Lowe T. Impact Of Hyponatremia On Patient Outcomes And Health-Care Resource Utilization In Hospitalized Patients. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Annual Conference, 2011, Poster.

135.  Dasta JF, Chiong JR, Kim S, Lin J, Evaluation Of The Hospital Resource Utilization Associated With Tolvaptan Usage Among Heart Failure Patients With Hyponatremia From The Everest Trial. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Annual Conference, 2011, Poster.

136.  Amin A, Princic N, Lin J, Thompson S and Johnston S. Duration of Risk of Venous Thromboembolism in Real-World US Surgical Patients. Anticoagulation Forum’s 11th National Conference on Anticoagulant Therapy, 2011, Poster.

137.  Amin A, Jhaveri M and Lin J. Rehospitalization Rates and Costs in Hospitalized ATHENA-Like US Patients With Atrial Fibrillation/Atrial Flutter.  Heart Rhythm Society (HRS) Conference, 2011. Oral Presentation.

138.  Amin A, Jhaveri M and Lin J. Cost Burden to US Payers of ATHENA-Like Patients With Atrial Fibrillation/Atrial Flutter. Heart Rhythm Society (HRS) Conference, 2011, Poster.

139.  Deitelzweig S, Thompson S, Lin J, McMorrow D and Johnson BH. Impact of CMS VTE Hospital Acquired Conditions (HAC) Policy on Hospital Cost and Revenue associated with Major Surgical Hip and Knee Procedures. 2011, Annual Meeting of Society of Hospital Medicine (SHM).

140.  Amin A, Deitelzweig S, Lin J, Belk K, Baumer D. Impact of Hyponatremia on Patient Outcomes and Health-Care Resource Utilization in Hospitalized Patients. 2011, Annual Meeting of Society of Hospital Medicine (SHM).

141.  Deitelzweig S, Amin A, Lin J, Baumer D, Belk K. Impact of hyponatremia on the readmission rates of hospitalized patients. 2011, Annual Meeting of Society of Hospital Medicine (SHM).

142.  Amin A, Varker H, Princic N, Lin J, Thompson S and Johnston S.  Duration of risk of venous thromboembolism in patients hospitalized for medical illnesses in the USA. 2011, Annual Meeting of Society of Hospital Medicine (SHM).

143.  Kim MH, Smith PJ, Jhaveri M, Lin J, Klingman D. Amiodarone and Sotalol in Atrial Fibrillation: Treatment Persistence and Occurrence of Adverse Events in the Real-World Setting 2011 American College of Cardiology (ACC).

144.  Alpert JS, Guerin A, Lin J, Jhaveri M and Wu EQ. Evaluation of International Normalized Ratio Monitoring and Anticoagulation Control in Atrial Fibrillation/Flutter Patients Using Warfarin and Antiarrhythmic Drug Therapy. 2011 American College of Cardiology (ACC).

145.  Guerin A, Lin J, Jhaveri M, Wu E and Alpert J. Real-World Clinical Outcomes and Costs in Atrial Fibrillation/Flutter Patients on Combined Warfarin and Antiarrhythmic Drug Therapy. American Managed Care Pharmacy (AMCP) Annual Conference, 2011, Poster.

146.  Amin A, Princic N, Lin J, Thompson S and Johnston S. Real-World Analysis of the Duration of Risk of Venous Thromboembolism In US Surgical Patients. 2010 Annual Meeting of the American Society of Hematology (ASH). Oral Presentation.

147.  Amin A, Lin J and Wiederkehr D. Real-World Analysis of Venous Thromboembolism Rates and Thromboprophylaxis Prescribing In US Patients with Cancer. 2010 Annual Meeting of the American Society of Hematology (ASH).

148.  Deitelzweig S, Thompson S, Lin J, McMorrow D and Johnson BH. Impact of CMS VTE Hospital Acquired Conditions (HAC) Policy on Hospital Cost and Revenue associated with Major Surgical Hip and Knee Procedures. 2010 Annual Meeting of the American Society of Hematology (ASH).

149.  Naccarelli GV, Johnston SS, Dalal M, Lin J and Patel PP. High Cost Burden of Atrial Fibrillation/Atrial Flutter in Older Patients (≥65 years) in the United States. American Heart Association Scientific Sessions (AHA) 2010.

150.  Amin A, Lin J and Wiederkehr D. Real-world Analysis of Deep Vein Thrombosis Prevention in Patients with Severe Lung Disease. American College of Chest Physicians (ACCP)-CHEST 2010.

151.  Amin A, Lin J and Wiederkehr D. Readmission for Venous Thromboembolism in US Patients Following Hospitalization for Major Orthopedic Surgery. American College of Surgeons (ACS) 2010 Clinical Congress. Oral Presentation.

152.  Amin A, Lin J and Wiederkehr D. Inpatient and Outpatient Rates of Venous Thromboembolism and Thromboprophylaxis in US Patients following Major Abdominal Surgery. American College of Surgeons (ACS) 2010 Clinical Congress.

153.  Amin A, Lin J and Wiederkehr D. Prevention of Deep-Vein Thrombosis across the Continuum Care in Patients with Congestive Heart Failure in the US. 14th Annual Scientific meeting of the Heart Failure Society of America (HFSA), 2010.

154.  Schulman KL, Johnston SS, Lin J and Huse D. Prevalence of Atrial Fibrillation (AF) in the US. 26th International Conference on Pharmacoepidemiology & Theraputic Risk Management, 2010.

155.  Deitelzweig S, Lin J, Johnson, BH and Schulman KL. Trends In The Prevalence Of Venous Thromboembolism In The United States. 21st International Thrombosis Congress, 2010. BEST POSTER AWARD.

156.  Amin A, Lin J and Wiederkehr D. Prevention Of Venous Thromboembolism In At-Risk Medical Patients In the USA. 21st International Thrombosis Congress, 2010.

157.  Amin A, Lin J and Wiederkehr D. Real-World Analysis of Venous Thromboembolism Prevention in US Patients with Ischemic Stroke. 135th Annual Meeting of the American Neurological Association, 2010.

158.  Pineo G, Lin J, Stern L, Subrahmanian T. Robust Univariate And Multivariate Sensitivity Analysis Confirm That Enoxaparin Is Costsaving To The Payers Compared With Ufh For Vte Prevention In Patients With Ischemic Stroke: Analysis Of The Prevail Data. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, 2010. 

159.  Emons MF, Lin J, Yu HT. Treatment Patterns In Atrial Fibrillation: Agents Used In Current Patient Management. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, 2010. 

160.  Emons MF, Lin J, Yu HT. Inpatient Mortality And Hospitalization Costs In Atrial Fibrillation Patients. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, 2010.

161.  Naccarelli GV, Varker H, Lin J and Schulman K. Effect of Ethnicity on Prevalence of Atrial Fibrillation Among Medicaid Patients. Heart Rhythm Society (HRS) Conference, 2010.

162.  Kim MH, Lin J, Foltz Boklage SH and Kreilick CA. Comparative Cost Of Ablation In Atrial Fibrillation Patients Stratified By Procedural Success Versus Failure: Implications For Resource Utilization In Medicare-Aged Ablation Candidates In The United States. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, 2010.  Oral Presentation.

163.  Schulman KL, Johnston SS, Lin J and Huse D. Projecting Disease Prevalence: The Impact Of Methodology– Examples In Atrial Fibrillation, International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, 2010.  Workshop Panel Lead.

164.  Deitelzweig S, Lin J and Lin G. Preventing venous thromboembolism following hip replacement surgery: analysis of special populations who require alterations to anticoagulant regimens. 2010, Annual Meeting of Society of Hospital Medicine (SHM).

165.  Kim, M.H., Lin J, Chu, BC and Schulman, KL. Total Healthcare Costs Among Atrial Fibrillation Patients in the United States in 2010. 2010 American College of Cardiology (ACC).

166.  Kim, M.H., Johnson, SS, Lin J and Schulman, KL. Estimate of Incremental Cardiovascular Healthcare Costs in Patients with Atrial Fibrillation in the United States. 2010 American College of Cardiology (ACC).

167.  Amin A, Lin J and Ryan A. VTE Prophylaxis Across the Continuum of Care in US Orthopedic Surgery Patients. 2009 Annual Meeting of the American Society of Hematology (ASH).

168.  Deitelzweig S, Lin J, Johnson, BH and Schulman KL. Prevalence of Venous Thromboembolism Across Ethnic Groups in the United States. 2009 Annual Meeting of the American Society of Hematology (ASH).

169.  Merli GJ, Malangone E, Lin J and Stern L. Real-world VTE prophylaxis practices in US orthopedic surgery patients: an analysis of an integrated healthcare database. 2009 Annual Meeting of the American Society of Hematology (ASH).

170.  Amin A, Lin J and Ryan A. VTE Prophylaxis Across the Continuum of Care in US Medical Patients at Risk of Venous Thromboembolism. 2009 Annual Meeting of the American Society of Hematology (ASH).

171.  Deitelzweig S, Lin J, Johnson BH, Schulman KL. Current trends and future projections on the prevalence of venous thromboembolism in the USA, National Conference on Blood Disorders in Public Health, 2009. Oral Presentation.

172.  Patel PP, Johnston SS, Lin J, Schulman KL, Naccarelli GV Hospitalization And Mortality In Advanced-Age Patients With Atrial Fibrillation/Atrial Flutter But Without Heart Failure In The United States. International Society of Pharmacoeconomics and Outcomes Research - ISPOR 12th Annual European Congress, 2009

173.  Patel PP, Naccarelli GV, Johnston SS, Lin J, Schulman KL Cost Burden Of Athena Endpoints In Athena-Like Patients With Atrial Fibrillation/Atrial Flutter But Without Heart Failure In The United States.  International Society of Pharmacoeconomics and Outcomes Research - ISPOR 12th Annual European Congress, 2009

174.  Amin AN, Lin J, Johnson BH, Schulman KL Economic Outcomes in Patients at Risk of Venous Thromboembolism Receiving Best-Practice Appropriate Prophylaxis or Partial Prophylaxis, American College of Chest Physicians (ACCP) Annual Conference, 2009

175.  Amin AN, Lin J, Ryan A. VTE Prophylaxis Across the Continuum of Care in US Medical and Surgical Patients at Risk of Venous Thromboembolism. American College of Chest Physicians (ACCP) Annual Conference, 2009

176.  Amin AN and Lin J. Hospital Acquired Venous Thromboembolism Rates Following Prophylaxis with Enoxaparin and Dalteparin. American College of Chest Physicians (ACCP) Annual Conference, 2009

177.  Amin A, Lin J and, Ryan A. Analysis of inpatient and outpatient venous thromboembolism prophylaxis patterns in US critical care patients. American College of Chest Physicians (ACCP) Annual Conference, 2009. Oral Presentation.

178.  Deitelzweig S, Lin J, Johnson BH, Schulman KL. Prevalence Of Venous Thromboembolism In The Usa: Now And Future.  XXII Congress of The International Society on Thrombosis and Haemostasis (ISTH), 2009. Oral Presentation.

179.  Pineo G, Lin J, Stern L, Subrahmanian T. Enoxaparin Is Cost-Saving Compared With Unfractionated Heparin (Ufh) For Venous Thromboembolism Prophylaxis In Patients With Acute Ischemic Stroke: An Analysis Of Hospital Costs From The Prevail Trial.  XXII Congress of The International Society on Thrombosis and Haemostasis (ISTH), 2009

180.  Amin AN, Hussein M, Battleman D, Lin J, Stemkowski S, Merli G. Appropriate Vte Prophylaxis, Compared With Partial Vte Prophylaxis, Leads To Lower Vte Recurrence And Cost In Us Medical Patients.  XXII Congress of The International Society on Thrombosis and Haemostasis (ISTH), 2009

181.  Pineo G, Lin J, Stern L, Subrahmanian T. Enoxaparin For Venous Thromboembolism (VTE) Prophylaxis In Patients With Acute Ischemic Stroke Is Associated With Lower Costs To The Payers Than Unfractionated Heparin (UFH): Analysis From The Prevail Trial.  XXII Congress of The International Society on Thrombosis and Haemostasis (ISTH), 2009

182.  Amin, A., Lin J. and Ryan A. VTE prophylaxis across the continuum of care in US cancer patients. Publication-only. American Society of Clinical Oncologists (ASCO), 2009

183.  Kim, M.H., Lin J., Hussein, M., Kreilick, C. and Battleman D. How Much Does it Cost to Manage Atrial Fibrillation in the United States? AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2009

184.  Kim, M.H., Lin J. and Kreilick C. A National Assessment of Medicare Prescription Coverage Gaps Among Atrial Fibrillation Patients. AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2009

185.  Patel, P.P., Gregory, C., Lin J., Schulman, K.L. and Naccarelli, G.V. Hospitalization and Mortality in Patients With Atrial Fibrillation/Atrial Flutter and Among ATHENA-Like Patients in the United States. AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2009

186.  Patel, P.P., Johnston, S.J., Lin J., Schulman, K.L. and Naccarelli, G.V. Cost Burden of Hospitalization and Mortality in United States Atrial Fibrillation/Flutter Patients. Heart Rhythm Society (HRS) Conference, 2009

187.  Naccarelli, G.V., Johnston, S.J., Lin J., Patel, P.P. and Schulman, K.L. Cost Burden of ATHENA Endpoints in United States Atrial Fibrillation/Atrial Flutter Patients. Heart Rhythm Society (HRS) Conference, 2009

188.  Thosani, A.J., Xiong, Y., Lin J., Kothawala, P. and Zimetbaum, P.J. Are Atrial Fibrillation Patients Receiving Anticoagulation in Accordance With Their Stroke Risk?  Heart Rhythm Society (HRS) Conference, 2009

189.  Amin A.N., Lin J., Johnson B., Schulman K.L. Clinical Outcomes in Patients at Risk of Venous Thromboembolism Receiving Appropriate or Partial Prophylaxis. American Thoracic Society (ATS) International Conference, 2009

190.  Kim, M.H.,  Klingman, D., Lin J., Battleman, D. Incidence and Temporal Pattern of Hospital Readmissions for Atrial Fibrillation in Managed Care Patients Following Prior Hospitalization for this Condition. American Managed Care Pharmacy (AMCP) Annual Conference, 2009

191.  Kim M., Klingman D., Lin J., Battleman D. Patterns and predictors of discontinuation of rhythm-control therapy in patients with newly diagnosed atrial fibrillation.  American College of Cardiology (ACC), 2009

192.  Kim M., Klingman D., Lin J., Battleman D. What's the price for maintaining normal sinus rhythm? - Economics of prerequisite admission for antiarrhythmic drug initiation in atrial fibrillation. American College of Cardiology (ACC), 2009

193.  Naccarelli G.V., Varker H., Lin J., Schulman K. Increasing prevalence of atrial fibrillation and flutter in the United States: is it just due to the population aging? American College of Cardiology (ACC), 2009

194.  Ishak K.J., Proskorovsky I., Guo S., Lin J., Caro J.J. The impact of drug-related side-effects on persistence with amiodarone or sotalol in the management of atrial fibrillation: An exploratory analysis. AHA-49th Cardiovascular Disease Epidemiology and Prevention, 2009

195.  Deitelzweig S., Hussein M., Lin J., Kreilick C., Battleman D. Patterns and Predictors of Warfarin Use in Patients with Venous Thromboembolism. 2008 Annual Meeting of the American Society of Hematology (ASH).

196.  Spyropoulos A.C., Hussein M., Lin J., Battleman D. Rates of Venous Thromboembolism in Commercially Insured US Surgical Patients. 2008 Annual Meeting of the American Society of Hematology (ASH). Oral Presentation.

197.  Amin A.N., Lin J., Lenhart G., Schulman K.L. Economic Outcomes in Patients at Risk for Venous Thromboembolism Receiving Appropriate Enoxaparin or Unfractionated Heparin Prophylaxis. 2008 Annual Meeting of the American Society of Hematology (ASH).

198.  Amin A.N., Lin J., Yang G. and Stemkowski S. Clinical and Economic Outcomes Following Full or Partial ACCP Recommended Prophylaxis in Cancer Patients at Risk of Venous Thromboembolism.  2008 Annual Meeting of the American Society of Hematology (ASH). Oral Presentation.

199.  Amin, A.N., Hussein M., Battleman D., Lin J., Stemkowski S. and Merli G.J. Appropriate VTE Prophylaxis Is Associated with Lower Direct Medical Costs among Medical and Surgical Patients in the United States. 2008 Annual Meeting of the American Society of Hematology (ASH).

200.  Ishak K.J., Proskorovsky I., Guo S., Lin J., Caro J.J. Impact of non-persistence with amiodarone or sotalol on recurrence of atrial fibrillation. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) European Congress 2008.

201.  Deitelzweig S., Lin J., Hussein M., Battleman D. Are surgical patients at-risk of venous thromboembolism currently meeting the surgical care improvement performance measure for appropriate and timely prophylaxis? American College of CHEST Physicians (ACCP) 2008 Meeting.

202.  Spyropoulos A.C., Hussein M., Lin J., Battleman D. Rates of venous thromboembolism occurrence in medical patients among the insured population. American College of CHEST Physicians (ACCP) 2008 Meeting.

203.  Merli G., Ferrufino C., Lin J., Hussein M., Battleman D. Total hospital-based costs of enoxaparin or fondaparinux prophylaxis in patients at risk of venous thromboembolism. American College of CHEST Physicians (ACCP) 2008 Meeting.

204.  Amin, A., Lin J., Yang, G and Stemkowski, S. Examining the rate of appropriate, ACCP-recommended VTE prophylaxis use in heart failure patients.  September 2008, 12th Annual Scientific Meeting of Heart Failure Society of America.

205.  Merli, G., Ferrufino, C., Lin J., Hussein, M., Battleman, D. Hospital-based Costs of Venous Thromboembolism Prophylaxis in Hospitalized Patients: a Retrospective Transactional Records Analysis, May 2008, Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, sponsored by the American Heart Association (AHA)/American Stroke Association.

206.  Amin, A., Yang, G, Lin J. and Stemkowski, S. Rates of guideline-recommended venous thromboembolism prophylaxis in US hospital patients, April 2008, Annual Meeting of Society of Hospital Medicine (SHM).

207.  Deitelzweig S., Lin J., Becker R., Benner J.  2-year costs of enoxaparin prophylaxis, unfractionated heparin prophylaxis, or no prophylaxis in medical patients at risk of venous thromboembolism. 2008 Annual Meeting of Society of Hospital Medicine (SHM).

208.  Amin, A., Yang, G, Lin J. and Stemkowski, S. Are hospitalized US medical patients receiving appropriate VTE prophylaxis? 2008, Annual Meeting of Society of General Internal Medincine( SGIM).

209.  Amin, A., Lin J., Yang, G and Stemkowski, S. VTE prophylaxis use in severe lung disease patients, 2008, Annual Meeting of American Thoracic Society (ATS).

210.  Amin, A., Lin J., Yang, G and Stemkowski, S. Rates of guideline-recommended venous thromboembolism prophylaxis in US hospital critical care patients, 2008, Annual Scientific Session of American College of Cardiology (ACC).

211.  Deitelzweig S., Becker R., Lin J., Benner J.  Comparison of the 2−Year Clinical Outcomes of VTE Prophylaxis Options in Medical Patients at Risk of VTE. 2007 Annual Meeting of the American Society of Hematology (ASH).

212.  Amin, A., Stemkowski, S., Lin J. and Yang, G. Rates of Guideline-Recommended Venous Thromboembolism Prophylaxis in Surgical Patients Among US Hospitals: A Real-World Analysis. 2007 Annual Meeting of the American Society of Hematology (ASH).

213.  Merli, G., Ferrufino, C., Lin J. and Hussein M. Low Molecular Weight Heparin Reduces the Cost of Venous Thromboembolism Treatment Compared with Unfractionated Heparin in US Hospitals. 2007 Annual Meeting of the American Society of Hematology (ASH).

214.  Deitelzweig S., Becker R., Lin J., Benner J.  Identifying VTE prophylaxis-related costs and outcomes, 19th Annual National Forum, Institute for Healthcare Improvement (IHI).

215.  Amin, A., Stemkowski, S.A., Lin J., and Yang G. (June 2007) Assessing adherence to the American College of Chest Physicians’ recommendations for thromboprophylaxis in hospitalized cancer patients, American Society of Clinical Oncology (ASCO) 2007 Annual Meeting.

216.  Merli, G., Ferrufino, C., Lin J. and Hussein M. (May 2007)  Venous Thromboembolism (VTE) Treatment With Low Molecular Weight Heparin Reduces Total Hospital Costs And VTE-Related Readmission, 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, sponsored by the American Heart Association (AHA)/American Stroke Association.

217.  Stemkowski, S.A., Lin J., Yang G. and Amin, A. (May 2007) VTE Prophylaxis in US Hospitals, 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, sponsored by the American Heart Association (AHA)/American Stroke Association.

218.  Amin, A., Stemkowski, S.A., Lin J., and Yang G. (April 2007) Assessing Adherence to the American College of Chest Physicians’ (ACCP) Recommendations for Thromboprophylaxis in Hospitalized Acute Medical Patients, Society of General Internal Medicine (SGIM) 30th Annual Meeting; Oral Presentation.

219.  Ferrufino, C., Lin J. and Hussein M. (April 2007)  Inpatient use of low molecular weight heparin (LMWH) reduces hospital-based treatment costs associated with venous thromboembolism (VTE) prophylaxis, Society of General Internal Medicine (SGIM) 30th Annual Meeting.

220.  Amin, A., Stemkowski, S.A., Lin J., and Yang G. (Feb. 2007) Improving Preventive Care: Assessing Adherence To The Sixth American College Of Chest Physicians’ Recommendations For Thromboprophylaxis In At-Risk Cardiovascular And Stroke Patients In Us Hospitals, American Federation for Medical Research (AFMR), 2007 Western Region Meeting.

221.  Amin, A., Stemkowski, S.A., Lin J., and Yang G. (Feb. 2007) Improving Preventive Care: Assessing Adherence To The Sixth American College Of Chest Physicians’ Recommendations For Thromboprophylaxis In At-Risk Cardiovascular And Stroke Patients In Us Hospitals, American Federation for Medical Research (AFMR), 2007 Western Region Meeting; Oral Presentation.

222.  Spyropoulos, A. and Lin J.  (Dec. 2006) Economic burden of venous thromboembolism from a health plan perspective across the USA, 41st American Society of Health-system Pharmacy (ASHP) Midyear Clinical Meeting and Exhibition

223.  Amin, A., Stemkowski, S.A., Lin J., and Yang G. (Dec. 2006) Thromboprophylaxis in US hospitals: adherence to the sixth American College of Chest Physicians’ recommendations for at-risk medical and surgical patients. 41st American Society of Health-system Pharmacy (ASHP) Midyear Clinical Meeting and Exhibition

224.  Amin, A., Stemkowski, S.A., Lin J., and Yang G. (Nov. 2006) Thromboprophylaxis compliance in U.S. hospitals: adherence to the sixth American College of Chest Physician’s recommendations for at-risk medical patients; American College of CHEST Physicians (ACCP) 2007  Meeting, Abstracts 2006 130: 87S-c; Oral Presentation.

225.  Spyropoulos, A. and Lin J.  (Nov. 2006) Hospital readmission and economic burden of venous thromboembolism: from a health plan perspective; American College of CHEST Physicians (ACCP) 2007  Meeting, Abstracts 2006 130: 260S-a.

226.  Yu, H., Dylan, M.L., Lin J., and Dubois, R.W., (May 2006) Prophylaxis of Venous Thromboemblism: Do Providers Follow Guidelines?  7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, sponsored by the American Heart Association (AHA) /American Stroke Association.